前列地尔联合替米沙坦对早期糖尿病肾病患者血流变学和肾功能的影响
程艳荣，王琳，张麦浪
（西安高新医院内分泌科，陕西 西安，710077）
浏览次数：68次 下载次数：400次
摘要：
目的 探究前列地尔联合替米沙坦对早期糖尿病肾病患者血流变学和肾功能的影响。方法 将我院接诊的110例糖尿病肾病患者根据随机数字表法分为对照组和观察组，各55例。对照组予以替米沙坦治疗，观察组予以前列地尔联合替米沙坦治疗。比较两组的治疗总有效率、血流变学及肾功能情况。结果 观察组患者的治疗总有效率为94.55%，高于对照组的 74.55%（P<0.05）；治疗后，两组患者的血流变学指标和肾功能指标均改善，且观察组优于对照组（P<0.05）。结论 对早期糖尿 病肾病患者予以前列地尔联合替米沙坦治疗，效果确切，可改善患者的血流变学及肾功能。
关键词：前列地尔；替米沙坦；糖尿病肾病；血流变学；肾功能
中图分类号：R587.2文献标志码：A文章编号：2096-1413(2017)22-0021-02
Influence of alprostadil combined with telmisartan on hemorrheology and renal function in patients with
early diabetic nephropathy
CHENG Yan-rong, WANG Lin, ZHANG Mai-lang
(Department of Endocrinology, Xi``an Gaoxin Hospital, Xi``an 710077, China)
ABSTRACT: Objective To explore the influence of alprostadil combined with telmisartan on hemorrheology and renal function in patients with early diabetic nephropathy. Methods One hundred and ten cases of patients with early diabetic nephropathy in our hospital were randomly divided into control group and observation group, with 55 cases in each group. The control group was treated with telmisartan, and the observation group used alprostadil combined with telmisartan. The total effective rates, hemodynamics and renal function were compared between the two groups. Results The total effective rate of the observation group was 94.55%, which was higher than 74.55% of the control group (P<0.05). After treatment, the hemodynamics and renal function indexes in the two groups improved, and those in the observation group were better than the control group (P<0.05). Conclusion For patients with early diabetic nephropathy, alprostadil combined with telmisartan is effective and can improve the hemodynamics and renal function of patients.
KEYWORDS: alprostadil; telmisartan; diabetic nephropathy; hemorrheology; renal function
参考文献：
[1] 刘俊成,徐刚,张旭力.糖尿病肾病患者感染病原菌耐药性分析与对肾功能的影响研究[J].中华医院感染学杂志,2016,26(2):338-340.
[2] 华瑞芳,刘勇,曾小兵.2 型糖尿病肾病血液透析患者感染病原菌分布及对肾功能影响的研究[J].中华医院感染学杂志,2016,26(13):2985-2987.
[3] 张丽,皇甫建,肖瑞.糖尿病肾病病人血浆FABP4 水平变化及其与PTEN 相关性的研究进展[J].中西医结合心脑血管病杂志,2016,14(6):606-609.
[4] 王卫民.前列地尔联合厄贝沙坦治疗早期糖尿病肾病的临床效果 [J].中国综合临床,2016,32(5):434-437.
[5] 梁虹,高海娥,李飞.糖尿病肾病尿毒症患者尿路感染危险因素分析与预防[J].中华医院感染学杂志,2016,26(5):1056-1058.
[6] 刘玉才,徐飞.前列地尔治疗糖尿病肾病的机制及临床应用[J].中国老年学杂志,2016,36(2):500-501.
[7] 刘浩.前列地尔联合替米沙坦治疗糖尿病肾病疗效观察[J].蚌埠医学院学报,2016,41(7):861-862,865.
[8] 王洪涛,黄远丽.骨化三醇胶丸联合替米沙坦片治疗早期糖尿病肾病的临床疗效[J].安徽医药,2016,20(4):790-792.
[9] 杨杰,沈丰平,周全荣.不同疗程前列地尔治疗临床期域型糖尿病肾病临床观察[J].浙江临床医学,2016,18(2):301-302.
[10] 程莉,苏虹梅.前列地尔联合替米沙坦对慢性肾小球肾炎患者血 t-PA 与PAI-1的影响及其意义[J].医学综述,2016,21(6):1110-1112.